Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions
Metastatic Renal Cell Carcinoma
Trial Locations (23)

13005

Hospital Universitario Ciudad Real, Ciudad Real

13600

Complejo Hospitalario la Mancha Centro, Alcázar de San Juan

14004

H. Reina Sofía de Cordoba, Córdoba

15405

Hospital Arquitecto Marcide de Ferrol, Ferrol

17007

ICO Girona (Hospital Dr.Josep Trueta), Girona

23007

Complejo Hospitalario de Jaén, Jaén

24071

Complejo Hospitalario de León, León

28006

Hospital Universitario La Princesa / Servicio de Oncología Médica, Madrid

31008

Complejo Hospitalario de Navarra, Pamplona

32005

Complejo Hospitalario Ourense. Hospital Santa María Nai, Ourense

33011

Hospital General de Asturias, Oviedo

38320

Hospital Universitario Canarias, Santa Cruz de Tenerife

43003

Hospital de Sant Pau i Santa Tecla, Tarragona

43204

Hospital Universitario Sant Joan de Reus / Servicio de Oncología Médica, Reus

45071

Hospital Virgen de la Salud, Toledo

46011

Hospital Clínico Universitario de Valencia, Valencia

48960

Hospital Galdakano, Usansolo

50009

H Clínico Zaragoza, Zaragoza

08402

Hospital Asil de Granollers, Granollers

08208

Hospital Parc Taulí, Sabadell

07120

Hospital Universitari Son Espases, Palma

06006

H. Universitario Infanta Cristina, Badajoz

08035

Hospital Vall de Hebrón, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

TFS Trial Form Support

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02789137 - Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment | Biotech Hunter | Biotech Hunter